Three independent yearly analyses of the spectrum and potency of metronidazole: a multicenter study of 1,108 contemporary anaerobic clinical isolates.
To comply with ongoing United States Food and Drug Administration (FDA) recommendations about the validation of prescribing information, in each of three years (1994, 1996, 1997) at six medical centers, metronidazole was tested against > or = 50 strains of a range of contemporary anaerobic clinical bacteria. Species having > or = 90% susceptibility (MIC, < or = 8 microg/ml) to metronidazole (fulfilling FDA requirements) included Bacteroides fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus, Fusobacterium spp. and Clostridium spp. Only Eubacterium spp. and anaerobic Gram-negative cocci failed to achieve the required proportion of susceptibility throughout the 3 year period. Metronidazole appears to remain highly active versus anaerobic species associated with strict anaerobic organisms.
University of Iowa College of Medicine, Iowa City, Iowa, USA.
M E
ME
Erwin
A M
AM
Fix
R N
RN
Jones
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology*; D006801:Humans; D008795:Metronidazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests / Q000379:methods / Q000592:standards; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards
D000900:Anti-Bacterial Agents; D008795:Metronidazole